Breast cancer version 3.2014

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce & 11 others Elizabeth C. Reed, Kilian E. Salerno, Lee Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, Rashmi Kumar

Research output: Contribution to journalReview article

120 Citations (Scopus)

Abstract

Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The NCCN Guidelines specific to management of large clinical stage II and III tumors are discussed in this article. These guidelines are the work of the members of the NCCN Breast Cancer Panel. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. Although not stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer.

Original languageEnglish (US)
Pages (from-to)542-590
Number of pages49
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Guidelines
Breast Neoplasms
Patient Participation
Neoplasms
Biological Therapy
Therapeutics
Cause of Death
Lung Neoplasms
Radiotherapy
Clinical Trials
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Gradishar, W. J., Anderson, B. O., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., ... Kumar, R. (2014). Breast cancer version 3.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(4), 542-590. https://doi.org/10.6004/jnccn.2014.0058

Breast cancer version 3.2014. / Gradishar, William J.; Anderson, Benjamin O.; Blair, Sarah L.; Burstein, Harold J.; Cyr, Amy; Elias, Anthony D.; Farrar, William B.; Forero, Andres; Giordano, Sharon Hermes; Goldstein, Lori J.; Hayes, Daniel F.; Hudis, Clifford A.; Isakoff, Steven J.; Ljung, Britt Marie E.; Marcom, P. Kelly; Mayer, Ingrid A.; McCormick, Beryl; Miller, Robert S.; Pegram, Mark; Pierce, Lori J.; Reed, Elizabeth C.; Salerno, Kilian E.; Schwartzberg, Lee; Smith, Mary Lou; Soliman, Hatem; Somlo, George; Ward, John H.; Wolff, Antonio C.; Zellars, Richard; Shead, Dorothy A.; Kumar, Rashmi.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 4, 01.01.2014, p. 542-590.

Research output: Contribution to journalReview article

Gradishar, WJ, Anderson, BO, Blair, SL, Burstein, HJ, Cyr, A, Elias, AD, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Hayes, DF, Hudis, CA, Isakoff, SJ, Ljung, BME, Marcom, PK, Mayer, IA, McCormick, B, Miller, RS, Pegram, M, Pierce, LJ, Reed, EC, Salerno, KE, Schwartzberg, L, Smith, ML, Soliman, H, Somlo, G, Ward, JH, Wolff, AC, Zellars, R, Shead, DA & Kumar, R 2014, 'Breast cancer version 3.2014', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 4, pp. 542-590. https://doi.org/10.6004/jnccn.2014.0058
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD et al. Breast cancer version 3.2014. JNCCN Journal of the National Comprehensive Cancer Network. 2014 Jan 1;12(4):542-590. https://doi.org/10.6004/jnccn.2014.0058
Gradishar, William J. ; Anderson, Benjamin O. ; Blair, Sarah L. ; Burstein, Harold J. ; Cyr, Amy ; Elias, Anthony D. ; Farrar, William B. ; Forero, Andres ; Giordano, Sharon Hermes ; Goldstein, Lori J. ; Hayes, Daniel F. ; Hudis, Clifford A. ; Isakoff, Steven J. ; Ljung, Britt Marie E. ; Marcom, P. Kelly ; Mayer, Ingrid A. ; McCormick, Beryl ; Miller, Robert S. ; Pegram, Mark ; Pierce, Lori J. ; Reed, Elizabeth C. ; Salerno, Kilian E. ; Schwartzberg, Lee ; Smith, Mary Lou ; Soliman, Hatem ; Somlo, George ; Ward, John H. ; Wolff, Antonio C. ; Zellars, Richard ; Shead, Dorothy A. ; Kumar, Rashmi. / Breast cancer version 3.2014. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 4. pp. 542-590.
@article{68d40c9b7fba489c9e0de2ed35577e94,
title = "Breast cancer version 3.2014",
abstract = "Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The NCCN Guidelines specific to management of large clinical stage II and III tumors are discussed in this article. These guidelines are the work of the members of the NCCN Breast Cancer Panel. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. Although not stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer.",
author = "Gradishar, {William J.} and Anderson, {Benjamin O.} and Blair, {Sarah L.} and Burstein, {Harold J.} and Amy Cyr and Elias, {Anthony D.} and Farrar, {William B.} and Andres Forero and Giordano, {Sharon Hermes} and Goldstein, {Lori J.} and Hayes, {Daniel F.} and Hudis, {Clifford A.} and Isakoff, {Steven J.} and Ljung, {Britt Marie E.} and Marcom, {P. Kelly} and Mayer, {Ingrid A.} and Beryl McCormick and Miller, {Robert S.} and Mark Pegram and Pierce, {Lori J.} and Reed, {Elizabeth C.} and Salerno, {Kilian E.} and Lee Schwartzberg and Smith, {Mary Lou} and Hatem Soliman and George Somlo and Ward, {John H.} and Wolff, {Antonio C.} and Richard Zellars and Shead, {Dorothy A.} and Rashmi Kumar",
year = "2014",
month = "1",
day = "1",
doi = "10.6004/jnccn.2014.0058",
language = "English (US)",
volume = "12",
pages = "542--590",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Breast cancer version 3.2014

AU - Gradishar, William J.

AU - Anderson, Benjamin O.

AU - Blair, Sarah L.

AU - Burstein, Harold J.

AU - Cyr, Amy

AU - Elias, Anthony D.

AU - Farrar, William B.

AU - Forero, Andres

AU - Giordano, Sharon Hermes

AU - Goldstein, Lori J.

AU - Hayes, Daniel F.

AU - Hudis, Clifford A.

AU - Isakoff, Steven J.

AU - Ljung, Britt Marie E.

AU - Marcom, P. Kelly

AU - Mayer, Ingrid A.

AU - McCormick, Beryl

AU - Miller, Robert S.

AU - Pegram, Mark

AU - Pierce, Lori J.

AU - Reed, Elizabeth C.

AU - Salerno, Kilian E.

AU - Schwartzberg, Lee

AU - Smith, Mary Lou

AU - Soliman, Hatem

AU - Somlo, George

AU - Ward, John H.

AU - Wolff, Antonio C.

AU - Zellars, Richard

AU - Shead, Dorothy A.

AU - Kumar, Rashmi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The NCCN Guidelines specific to management of large clinical stage II and III tumors are discussed in this article. These guidelines are the work of the members of the NCCN Breast Cancer Panel. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. Although not stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer.

AB - Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The NCCN Guidelines specific to management of large clinical stage II and III tumors are discussed in this article. These guidelines are the work of the members of the NCCN Breast Cancer Panel. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. Although not stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84900458585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900458585&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0058

DO - 10.6004/jnccn.2014.0058

M3 - Review article

VL - 12

SP - 542

EP - 590

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 4

ER -